News

Filter

1 to 9 of 20 results

European prescribing trends for mCR prostate cancer

20-11-2014

Johnson & Johnson/AstraZeneca’s Zytiga (abiraterone acetate) is the clear agent of choice for second-line…

Astellas PharmaAstraZenecaBayerDendreonFranceGermanyItalyJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalProvengeSpainUKXofigoXtandiZytiga

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

Prostate cancer market to almost double to $8 billion by 2019, says GBI

21-11-2013

The prostate cancer treatment market is forecast to increase from $4.1 billion in 2012 to $8 billion…

Active BiotechAstellas PharmaJohnson & JohnsonMarkets & MarketingOncoGenexOncologyPharmaceuticalTeva Pharmaceutical IndustriesXofigoXtandiZytiga

Prostate cancer market set to grow 50% by 2021: report

06-09-2013

The increasing number of sufferers and the uptake of new drugs will see the prostate cancer market grow…

Asia-PacificAstellas PharmaEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalXtandiZytiga

Six months post launch, US prescribing trends for Xtandi

07-05-2013

At six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists…

3MAstellas PharmaJevtanaJohnson & JohnsonMarkets & MarketingMedivationNorth AmericaOncologyPharmaceuticalSanofiXtandiZytiga

BioTrends views Xeljanz and Zytiga prescribing in USA

26-03-2013

After around two months on the market, 37% of US rheumatologists have prescribed Pfizer's (NYSE: PFE)…

Anti-Arthritics/RheumaticsAstellas PharmaBiotechnologyJevtanaJohnson & JohnsonMedivationNorth AmericaOncologyPfizerPharmaceuticalSanofiXeljanzXtandiZytiga

Regulatory briefs from Astellas, Janssen, Biogen and Elan, and QRxPharma

17-01-2013

The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says the US Food and Drug Administration…

Anti-viralsAstellas PharmaBiogen IdecBiotechnologyElanEuropeJanssenJohnson & JohnsonMoxDuoNeurologicalNorth AmericaOncologyPharmaceuticalPrezistaQRxPharmaRegulationTarcevaTysabri

New drug options for advanced prostate cancer

13-12-2012

Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists…

AlpharadinAstellas PharmaBayerGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

1 to 9 of 20 results

COMPANY SPOTLIGHT

Menarini

Back to top